Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive)；~2. Subjects with body weight of ≥50 kg and ≤ 75 kg and BMI ≥18 and \<28 kg/m2 ;~3. Subjects and their partners were willing to use medically approved contraceptive methods within 6 months of study administration, partners did not plan to become pregnant, subjects did not plan to donate sperm；~4. The subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; Moreover, the subjects can communicate well with researchers and complete the research according to the regulations；~5. Subjects voluntarily sign ICF prior to the study.~Exclusion Criteria:~1. After comprehensive examination (vital signs, physical examination, electrocardiogram, chest radiography, abdominal B-ultrasound, blood routine, urine routine, blood biochemistry, etc.), any examination item was judged abnormal by the investigator and had clinical significance;~2. Patients with serious diseases such as cardiovascular system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematopoietic system, immune system, or any of the above diseases；~3. Patients with currently active infected diseases；~4. Subjects with past or current inflammatory bowel disease;~5. History of malignant neoplasms within the last 5 years (other than completely resected basal cell or squamous cell carcinoma of the skin in situ)；~6. Any one of HBV surface antigen, HCV antibody, HIV antibody, treponema pallidum antibody positive；~7. Subjects with T-SPOT test positive；~8. Those who smoked more than 5 cigarettes per day in the 6 months before screening and did not cooperate with smoking bans during the study period；~9. Alcoholics，or participants who consumed more than 14 units of alcohol per week (1 unit = 17.7mL ethanol, i.e., 1 unit = 357mL 5% beer or 43mL 40% liquor or 147mL 12% wine) during the preceding 3 months were screened，or who have positive result in blood-test of alcohol or not willing to ban alcohol；~10. Drug abusers, or drug users in the 3 months prior to screening, or excessive daily consumption of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to screening, or positive urine drug screening；~11. Surgery within 4 weeks prior to screening; Or plan to have surgery during the study period；~12. Use of any prescription drug, over-the-counter drug or health product within 4 weeks prior to screening, or prior use of such drug or health product within 5 half-lives, whichever is longer；~13. Those who have used any biological agent, including live vaccine, in the 3 months prior to screening, or who plan to receive live vaccine during the study period；~14. Anti-il-17 antibody active ingredient, excipients or latex allergy；~15. Those with anti-IL-17 antibody and anti-drug antibody positive；~16. Those who have been enrolled in other clinical studies or less than 3 months since the end of the most recent clinical study；~17. Those who had lost blood or donated at least 400 mL in the 3 months prior to the trial, or had lost blood or donated at least 200 mL in the 1 month prior to screening, or planned to donate blood during the trial；~18. Those who Can not tolerate venipunction, has a history of dizziness of needle and blood；~19. Those who have special dietary requirements, or can not accept uniform diet；~20. Other conditions considered inappropriate to be included in this study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Biosimilar Product (Type: EXPERIMENTAL): CMAB015 150 mg Subcutaneous injection in upper arm
- Reference Product (Type: ACTIVE_COMPARATOR): Cosentyx（Secukinumab ） 150 mg Subcutaneous injection in upper arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete